Answer
The safety and efficacy of Poteligeo (mogamulizumab) in children and adolescents under 18 years have not been established, and no data are available.
Sources for this answer
- Poteligeo 4 mg/mL, Concentrate for Solution for InfusionKyowa Kirin Ltd · emc · SmPC §4.2 Posology and method of administration · Version 8Document updated
Sources checked